ombitasvir​/paritaprevir/​ritonavir

Action and Spectrum

Drug Interaction

Adverse Reaction

>10%: 

Asthenia 

1-10%: 

Fatigue 

Insomnia 

Allergic skin reaction 

Pruritis 

Nausea  

Frequency undefined: 

Decreased hemoglobin 

Anemia 

Black Box Warning

Contraindication / Caution

ombitasvir/​ paritaprevir/​ ritonavir is contraindicated in patients hypersensitive to the active ingredient and other excipients. 

Pregnancy / Lactation

Pregnancy consideration:  

The drug is not safe to be administered during pregnancy. 

Breastfeeding warnings:  

Do not breastfeed during drug therapy 

Pregnancy category: 

• Category A: well-controlled and satisfactory studies do not infer any risks to the fetus in the first or later trimester.        
• Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women        
• Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.       
• Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.        
• Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.        
• Category N: There is no data available for the drug under this category  

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name: ombitasvir, paritaprevir, ritonavir 

Pronounced: om-bi-tas-vir pari-tap-revir rit-o-na-vir 

Why do we use ombitasvir, paritaprevir, and ritonavir? 

Ombitasvir, paritaprevir, ritonavir belongs to the category of antihepaciviral drugs. The drug combination helps to treat chronic hepatitis C.